We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » US FDA Schedules First Public Meeting on Biosimilars Pathway
US FDA Schedules First Public Meeting on Biosimilars Pathway
October 14, 2010
The U.S. Food and Drug Administration (FDA) may end its silence on how an approval pathway for biosimilars will work once it gets feedback at its first public meeting on the topic next month.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor